CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
ANNUAL REPORT ON FORM 10-K
INDEX TO AUDITED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 89 |
| Financial Statements | |
| Balance Sheets | 92 |
| Statements of Operations and Comprehensive Income (Loss) | 93 |
| Statements of Stockholders’ Equity (Deficit) | 94 |
| Statements of Cash Flows | 95 |
| Notes to Financial Statements | 96 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.